Australian researchers have discovered a promising new strategy to suppress the growth of aggressive and hard-to-treat ...

A WEHI-led study reveals that blocking minor splicing – an RNA process critical for cell division – reduces tumour growth in ...

Australian researchers have discovered a promising new strategy to suppress the growth of aggressive and hard-to-treat ...

Australian researchers have discovered a promising new strategy to suppress the growth of aggressive and hard-to-treat cancers by targeting a specialised molecular process known as ‘minor splicing’.

Together, these studies uncover novel compensatory pathways that may be involved in tumor adaptation to inhibition of the KRAS–RAF–MEK–ERK pathway.

BOSTON--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with ...

Direct KRAS effector pathways involved in cell transformation & lung tumorigenesis RAF, PI3K and the RAL guanine exchange factor (RAL-GEF) were initially identified as essential components of RAS ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI. A new cancer drug candidate, developed through a collaboration between ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U ...

KRAS is one of the most commonly mutated genes in human cancers and it is found in more than 90% of ... Molecular pathway that impacts pancreatic cancer progression and response to treatment ...